About Edward Ludwig
Edward Ludwig is board chairman of GRIP Molecular Technologies, a Minnesota company that builds a CRISPR protease platform to detect pathogen RNA. The company announced him as chairman on March 9, 2021. He has more than 45 years in senior executive roles in the medical industry.
Ludwig joined Becton, Dickinson and Company in 1979 and retired in 2012 as chief executive officer and chairman. Earlier, he held various roles at Coopers and Lybrand, where he earned his CPA certificate. He is a former chairman of the board of AdvaMed, a medical technology association. As of March 2021, he served on the boards of CVS Health and Boston Scientific. He formerly served as a director of Xylem. He holds an MBA from Columbia University and a B.A. in economics and accounting from the College of the Holy Cross.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Edward Ludwig in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Edward Ludwig works with at each company, as listed on that company's latest Form D.
